Christina Barkauskas, MD
Basic profileChristina Barkauskas is a Respiratory physician affiliated with Duke University. OpenAlex indexes 62 publications with 6,823 citations (h-index 22); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
Sponsor: Duke University
- RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
Sponsor: Duke University
- RECOVER-SLEEP: Platform Protocol
Sponsor: Duke University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer IngelheimProgram year20241 paymentResearch$63,085
- United Therapeutics CorporationProgram year20211 payment$17
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.3%Kinase inhibitor55.3%Ofev100%Part D<11 patientsMetabolism & gastrointestinal
44.7%Corticosteroid44.7%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2014–2018 per NIH RePORTER. The latest:
- The role of Pdgfra+ fibroblasts in lung fibrosis and alveolar homeostasis
Duke University
FY2018$118,590K08HL122521 - The role of Pdgfra+ fibroblasts in lung fibrosis and alveolar homeostasis
Duke University
FY2017$116,659K08HL122521 - The role of Pdgfra+ fibroblasts in lung fibrosis and alveolar homeostasis
Duke University
FY2016$114,738K08HL122521
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
Scott Antonia, MD
Duke University
Justin Oldham, MD
University of Michigan
Fernando Martinez, MD
University of Massachusetts Chan Medical School
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”